AMPIO PHARMACEUTICALS, INC. AMPE Income Statement

Ampio pharmaceuticals, inc. (AMPE)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Product and service revenue, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21	21	12	12	12	12	12	12	12	12	12	-	6	-	-	-	-
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21	21	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating expenses
Research and development
-	-	-	-	-	-	-	-	-	3,437	1,992	3,062	1,604	1,605	1,752	2,768	4,275	4,388	3,617	3,077	3,884	2,861	6,153	5,567	7,794	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
4,254	5,493	3,427	2,136	1,564	1,485	1,184	2,114	2,044	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,419	4,736	2,786	-	2,135	1,551	-	3,636	1,402	991	618	629	415
Research and development - related party (Note 9)
-	-	-	-	-	-	-	-	-	-0	0	287	35	35	35	35	35	35	35	35	35	-53	66	66	34	-	-	-	-	-	-	-	-	-	2	17	14	10	22
General and administrative
1,767	1,652	1,744	1,444	1,112	1,051	756	1,016	1,530	1,438	1,113	1,340	1,362	1,306	1,555	1,563	2,110	2,869	1,646	2,666	1,873	-	-	3,327	2,658	-	1,536	1,732	1,311	2,885	677	727	1,536	960	1,371	567	1,604	1,792	705
Selling, general and administrative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,299	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses
6,021	7,145	5,172	3,581	2,676	2,537	1,940	3,131	3,574	4,876	3,106	4,690	3,003	2,948	3,343	4,367	6,422	7,294	5,300	5,779	5,793	-	-	-	10,487	7,549	5,955	6,469	4,098	3,769	2,813	2,278	3,008	4,562	2,776	1,576	2,237	2,432	1,143
Loss from operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-9,497	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense)
Interest income (expense)
11	23	8	21	24	-1	-3	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest (expense) income
-	-	-	-	-	-	-	-	-	-0	0	0	3	3	3	6	10	-	-1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest (expense) income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	8	10	3
Unrealized loss on fair value of debt instruments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,170	-5,585	-5,585	-5,585	-	-
Derivative gain
831	6,102	-2,054	3,981	-3,160	4,187	7,744	7,751	25,614	-38,311	-1,146	2,113	1,126	-199	-715	0	0	-	0	-	-	-	-	-	-	0	-251	-139	-126	73	208	-233	156	362	274	-1,243	-948	-	-
Unrealized loss on trading security
-	-	-	-	-	-	-	-	-	-	-	-31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on trading security
-	-	-	-	-	-	-	-	-	-	-	-	-30	-210	64	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12	44	-	-	7	3	-	1	3	4	6	7	3	3	2	2	2	0	0	0
Loss from equity investment in Aytu BioScience, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-690	-352	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income (expense)
842	6,126	-2,046	4,002	-3,136	4,062	7,741	7,751	25,614	-	-1,146	2,081	1,098	-406	-648	-684	-342	4	-1	12	44	126	5	7	3	4	-250	-136	-122	79	216	-229	160	364	276	-1,241	-6,542	-10	-2
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7,289	-5,301	-5,767	-5,749	-	-	-8,940	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from discontinued operations (Note 4)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,541	-2,276	-1,946	-1,842	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,830	-7,577	-7,713	-7,591	-10,152	-9,491	-8,932	-10,471	-7,860	-6,072	-6,417	-4,178	-	-2,583	-2,495	-	-	-	-	-	-	-
Net loss applicable to non-controlling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-616	-421	-358	-307	-240	-211	-241	-229	-192	-121	-175	-29	-	-	-	-	-	-	-	-	-	-
Net loss, before income tax
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,208	-	-2,583	-2,495	-2,835	-4,185	-2,493	-2,818	-8,779	-2,443	-
Foreign tax expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	82	-	-	-	-
Net (loss) income
-5,179	-1,019	-7,219	420	-5,812	1,525	5,801	4,620	22,039	-43,126	-4,252	-2,608	-1,904	-3,354	-3,992	-5,052	-6,764	-10,214	-7,156	-7,355	-7,283	-9,911	-9,280	-8,691	-10,242	-7,013	-6,193	-6,593	-4,208	-3,677	-2,583	-2,495	-2,835	-4,185	-2,575	-2,818	-8,779	-2,443	-1,146
Net (loss) income per common share: Basic
-0.03	0.00	-0.05	0.00	-0.05	-	0.06	0.05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (loss) income per common share: Diluted
-0.04	-0.01	-0.05	-0.03	-0.05	-	-0.02	-0.03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic weighted-average common share outstanding
159,054	154,062	142,207	115,031	111,104	-	96,930	86,300	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted average number of common shares outstanding: Diluted
160,558	152,458	142,207	118,770	111,104	-	115,346	92,999	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
From continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.14	-0.10	-0.11	-0.11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
From discontinuing operations and non-controlling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.06	-0.04	-0.03	-0.03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Basic and diluted net (loss) income per common share
-	-	-	-	-	-	-	-	0.27	-0.66	-0.06	-0.04	-0.03	-0.06	-0.07	-0.10	-0.13	-0.20	-0.14	-0.14	-0.14	-0.18	-0.18	-0.17	-0.23	-0.19	-0.16	-0.17	-0.11	-0.10	-0.07	-0.08	-0.09	-0.03	-0.09	-0.10	-0.49	-0.14	-0.07
Weighted average number of common shares outstanding
-	-	-	-	-	-	-	-	82,943	75,093	68,232	60,623	57,240	57,217	53,842	52,016	52,016	51,998	51,998	51,989	51,981	52,068	51,969	51,917	44,950	41,907	37,106	37,090	37,072	37,069	36,477	31,260	31,126	29,065	28,679	28,284	18,025	17,107	17,069